Trial · NCT05732883
The Use of Dexamethasone in Total Thyroidectomy to Improve Voice Outcome and Hypocalcaemia
NCT05732883, Phase 2, Unknown, Tseung Kwan O Hospital, Hong Kong
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The Use of Dexamethasone in Total Thyroidectomy to Improve Voice Outcome and Hypocalcaemia. Trials, record NCT05732883. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05732883
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Use of Dexamethasone in Total Thyroidectomy to Improve Voice Outcome and Hypocalcaemia
- NCT number
- NCT05732883
- Status
- Unknown
- Phases
- Phase 2
- Enrollment
- 100 participants, estimated
- Lead sponsor
- Tseung Kwan O Hospital, Hong Kong
- Conditions
- Voice Change, Hypocalcemia
- Interventions
- Dexamethasone, Normal saline
- First posted
- 2023-02-17
- Last updated
- 2024-07-09
Source ClinicalTrials.gov
Registered outcomes40
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Post-operative calcium and parathyroid hormone level on POD1 | Post-op 1 day | Serum calcium and parathyroid hormone level will be monitored |
| Primary | Post-operative calcium and parathyroid hormone level after 3 months post-op | Post-op 3 months | Serum calcium and parathyroid hormone level will be monitored |
| Primary | Post-operative calcium and parathyroid hormone level after 6 months post-op | Post-op 6 months | Serum calcium and parathyroid hormone level will be monitored |
| Primary | Voice Handicap Index (VHI-10) | Post-op 1 week | Subjective voice assessment consisting of 10 questions. Each question 0-4 score |
| Primary | Voice Handicap Index (VHI-10) | Post-op 3 months | Subjective voice assessment consisting of 10 questions. Each question 0-4 score |
| Primary | Voice Handicap Index (VHI-10) | Post-op 6 months | Subjective voice assessment consisting of 10 questions. Each question 0-4 score |
| Primary | Perceptual Evaluation: Cantonese Perceptual Evaluation of Voice (CanPEV) | Post-op 1 week | Objective voice assessment consisting of 10 questions. Each question 1-10 score. 1 being normal and 10 being the most severe voice dysfunction |
| Primary | Perceptual Evaluation: Cantonese Perceptual Evaluation of Voice (CanPEV) | Post-op 3 months | Objective voice assessment consisting of 10 questions. Each question 1-10 score. 1 being normal and 10 being the most severe voice dysfunction |
| Primary | Perceptual Evaluation: Cantonese Perceptual Evaluation of Voice (CanPEV) | Post-op 6 months | Objective voice assessment consisting of 10 questions. Each question 1-10 score. 1 being normal and 10 being the most severe voice dysfunction |
| Primary | Acoustic Evaluation | Post-op 1 week | Instruct patient to sustain vowel /a/ and to read aloud the Hong Kong passage at a comfortable pitch and loudness level for about 3-5 seconds. Keep a distance of 15cm from the microphone for recording. Highlight the middle 3 seconds for analysis. To assess the fundamental frequency (Hz) and performance (dB) |
1 to 10 of 40Source ClinicalTrials.gov
See all 40 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05732883
GET https://conductscience.org/api/trials/v1/NCT05732883/registered?page=2